MX2018008653A - Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina . - Google Patents
Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina .Info
- Publication number
- MX2018008653A MX2018008653A MX2018008653A MX2018008653A MX2018008653A MX 2018008653 A MX2018008653 A MX 2018008653A MX 2018008653 A MX2018008653 A MX 2018008653A MX 2018008653 A MX2018008653 A MX 2018008653A MX 2018008653 A MX2018008653 A MX 2018008653A
- Authority
- MX
- Mexico
- Prior art keywords
- azepine
- pyrido
- dopamine
- tetrahydro
- ligands
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
La presente invención proporciona compuestos de Fórmula I: (ver formula) y sales farmacéuticamente aceptables de los mismos en donde las variables R1, R2, R3, R4, R5, a y A son como se definen en la presente; procesos para la preparación de; intermedios utilizados en la preparación de; y composiciones que contienen dichos compuestos o sales, y sus usos para tratar trastornos mediados por D3 (o asociados con D3) que incluyen, por ejemplo, adicción a sustancias, abuso de sustancias, esquizofrenia (por ejemplo, sus síntomas cognitivos), deterioro cognitivo (por ejemplo, deterioro cognitivo asociado con esquizofrenia, AD o PD), enfermedad de Parkinson, manía, ansiedad, trastornos del control de impulsos, trastornos sexuales y depresión.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662279037P | 2016-01-15 | 2016-01-15 | |
PCT/IB2017/050094 WO2017122116A1 (en) | 2016-01-15 | 2017-01-09 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018008653A true MX2018008653A (es) | 2018-12-10 |
Family
ID=57838441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018008653A MX2018008653A (es) | 2016-01-15 | 2017-01-09 | Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina . |
Country Status (16)
Country | Link |
---|---|
US (2) | US10590128B2 (es) |
EP (1) | EP3402796B1 (es) |
JP (1) | JP6929857B2 (es) |
KR (1) | KR102206321B1 (es) |
CN (1) | CN108884093B (es) |
AU (1) | AU2017208119B2 (es) |
BR (1) | BR112018013955B1 (es) |
CA (1) | CA3011201C (es) |
ES (1) | ES2837018T3 (es) |
IL (1) | IL260298B (es) |
MX (1) | MX2018008653A (es) |
RU (1) | RU2712455C1 (es) |
SG (1) | SG11201805202VA (es) |
TW (1) | TWI633104B (es) |
WO (1) | WO2017122116A1 (es) |
ZA (1) | ZA201803776B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201805202VA (en) | 2016-01-15 | 2018-07-30 | Pfizer | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
KR20200112910A (ko) | 2018-01-26 | 2020-10-05 | 시오노기 앤드 컴파니, 리미티드 | 도파민 d3 수용체 길항 작용을 갖는 축환 화합물 |
CN108997287B (zh) * | 2018-07-23 | 2021-12-28 | 陕西师范大学 | 以四氟硼酸的离子液体为氟源催化合成4-氟代四氢吡喃衍生物的方法 |
CN109608451A (zh) * | 2018-12-17 | 2019-04-12 | 上海药明康德新药开发有限公司 | 一种2-氧亚基-吡啶并[2,3-d]氮杂卓-7(2H)-甲酸叔丁酯合成方法 |
WO2023172497A2 (en) * | 2022-03-07 | 2023-09-14 | Drexel University | Compounds, compositions, and methods for treating, ameliorating, and/or preventing ***e use disorder |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
ATE323680T1 (de) | 2002-02-13 | 2006-05-15 | Glaxo Group Ltd | 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen |
US20050085461A1 (en) | 2002-02-13 | 2005-04-21 | Cooper David G. | Benzenesulfonamide derivatives |
EP1661889A4 (en) | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
EP1694334B1 (en) | 2003-12-18 | 2011-10-19 | Abbott GmbH & Co. KG | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor |
US20050137186A1 (en) | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
GB0412314D0 (en) | 2004-06-02 | 2004-07-07 | Glaxo Group Ltd | Compounds |
ZA200701232B (en) * | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
WO2006103559A1 (en) | 2005-04-01 | 2006-10-05 | Warner-Lambert Company Llc | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia |
WO2007028132A2 (en) | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS |
WO2007140213A1 (en) | 2006-05-26 | 2007-12-06 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
WO2008009125A1 (en) * | 2006-07-20 | 2008-01-24 | Cascade Therapeutics Inc. | Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands |
GB0619176D0 (en) | 2006-09-29 | 2006-11-08 | Lectus Therapeutics Ltd | Ion channel modulators & uses thereof |
TWI432427B (zh) | 2006-10-23 | 2014-04-01 | Cephalon Inc | 作為ALK及c-MET抑制劑之2,4-二胺基嘧啶之融合雙環衍生物 |
GB0710844D0 (en) | 2007-06-06 | 2007-07-18 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
WO2009007965A2 (en) | 2007-07-09 | 2009-01-15 | Technion Research & Development Foundation Ltd | Routing methods for multiple geographical entities |
CN101712675B (zh) | 2008-10-07 | 2013-07-03 | 江苏恒谊药业有限公司 | 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用 |
EP2408454A2 (en) | 2009-03-18 | 2012-01-25 | Resverlogix Corp. | Novel anti-inflammatory agents |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
AU2012296662A1 (en) | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
US9416139B2 (en) | 2012-11-29 | 2016-08-16 | Sunshine Lake Pharma Co., Ltd. | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof |
WO2014106800A2 (en) | 2013-01-04 | 2014-07-10 | Aurigene Discovery Technologies Limited | Substituted 2-amino pyrimidine derivatives as kinase inhibitors |
GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
MD20150122A2 (ro) * | 2013-06-27 | 2016-05-31 | Pfizer Inc. | Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1 |
EP3021673A1 (en) | 2013-07-17 | 2016-05-25 | Bayer CropScience Aktiengesellschaft | Heterocyclic sulfonylamino(thio)carbonyl-derivatives with nematicidal properties |
SG11201805202VA (en) | 2016-01-15 | 2018-07-30 | Pfizer | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS |
-
2017
- 2017-01-09 SG SG11201805202VA patent/SG11201805202VA/en unknown
- 2017-01-09 EP EP17700748.1A patent/EP3402796B1/en active Active
- 2017-01-09 AU AU2017208119A patent/AU2017208119B2/en active Active
- 2017-01-09 JP JP2018536264A patent/JP6929857B2/ja active Active
- 2017-01-09 RU RU2018125942A patent/RU2712455C1/ru active
- 2017-01-09 US US16/069,585 patent/US10590128B2/en active Active
- 2017-01-09 BR BR112018013955-6A patent/BR112018013955B1/pt active IP Right Grant
- 2017-01-09 ES ES17700748T patent/ES2837018T3/es active Active
- 2017-01-09 WO PCT/IB2017/050094 patent/WO2017122116A1/en active Application Filing
- 2017-01-09 CN CN201780017459.4A patent/CN108884093B/zh active Active
- 2017-01-09 KR KR1020187023277A patent/KR102206321B1/ko active IP Right Grant
- 2017-01-09 CA CA3011201A patent/CA3011201C/en active Active
- 2017-01-09 MX MX2018008653A patent/MX2018008653A/es unknown
- 2017-01-13 TW TW106101286A patent/TWI633104B/zh active
-
2018
- 2018-06-07 ZA ZA2018/03776A patent/ZA201803776B/en unknown
- 2018-06-27 IL IL260298A patent/IL260298B/en unknown
-
2020
- 2020-01-23 US US16/750,505 patent/US11390623B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL260298A (en) | 2018-08-30 |
US20190047997A1 (en) | 2019-02-14 |
CN108884093A (zh) | 2018-11-23 |
JP6929857B2 (ja) | 2021-09-01 |
WO2017122116A1 (en) | 2017-07-20 |
US10590128B2 (en) | 2020-03-17 |
CN108884093B (zh) | 2021-07-09 |
JP2019501930A (ja) | 2019-01-24 |
ZA201803776B (en) | 2020-09-30 |
US20200157098A1 (en) | 2020-05-21 |
BR112018013955B1 (pt) | 2024-01-16 |
CA3011201A1 (en) | 2017-07-20 |
AU2017208119B2 (en) | 2019-11-07 |
RU2712455C1 (ru) | 2020-01-29 |
KR20180100432A (ko) | 2018-09-10 |
IL260298B (en) | 2021-07-29 |
CA3011201C (en) | 2020-09-22 |
ES2837018T3 (es) | 2021-06-29 |
EP3402796A1 (en) | 2018-11-21 |
BR112018013955A2 (pt) | 2018-12-11 |
KR102206321B1 (ko) | 2021-01-21 |
AU2017208119A1 (en) | 2018-06-28 |
US11390623B2 (en) | 2022-07-19 |
SG11201805202VA (en) | 2018-07-30 |
TW201736367A (zh) | 2017-10-16 |
EP3402796B1 (en) | 2020-11-18 |
TWI633104B (zh) | 2018-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018008653A (es) | Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina . | |
PH12015502502A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
GEP20207149B (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
PH12015502658A1 (en) | 3,4-dihydroisoquinolin-2 (1h)-yl compounds | |
TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
CL2012001139A1 (es) | Compuestos derivados de imidazo[1.2-b]piridazina, inhibidores de pde10; composicion farmaceutica; procedimiento de preparacion; util para el tratamiento o prevencion de un trastorno del snc, tales como trastornos psicoticos, de ansiedad, del movimiento, del humor, neurodegenerativos, metabolicos y del dolor, entre otros. | |
PH12015500883A1 (en) | Heteroaromatic compounds as dopamide d1 ligands | |
SG195085A1 (en) | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors | |
CL2008003787A1 (es) | Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras. | |
ME01532B (me) | Jedinjenja | |
PH12019500004A1 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
MX2009001036A (es) | Pirazolopirimidinas, proceso para su preparacion y su uso como medicina. | |
MX349556B (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). | |
PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
TN2015000018A1 (en) | 5-ht3 receptor antagonists | |
PH12016501993A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
IN2014DN09826A (es) | ||
MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
EA201990188A1 (ru) | Производные 5,7-дигидропирролопиридина |